Trehalose alleviates doxorubicin-induced cardiotoxicity in female Swiss albino mice by suppression of oxidative stress and autophagy

J Biochem Mol Toxicol. 2021 Sep;35(9):e22859. doi: 10.1002/jbt.22859. Epub 2021 Jul 30.

Abstract

Clinically, the use of doxorubicin (DOX) is limited due to DOX-induced cardiotoxicity (DIC). The current study aimed to evaluate the cardioprotective effect of trehalose (TRE) against DIC in a female Swiss albino mouse model. Mice were divided into five experimental groups: Gp. I: saline control group (200 μl/mouse saline three times per week for 3 weeks day after day), Gp. II: DOX-treated group (2 mg/kg body weight three times per week for 3 weeks day after day), Gp. III: TRE group (200 μg/mouse three times per week for 3 weeks day after day), Gp. IV: DOX + TRE cotreatment group (animals were coadministered with DOX and TRE as in Gp. II and III, respectively), and Gp. V: DOX + TRE posttreatment group (animals were treated with DOX as in Gp. II followed by treatment with TRE as in Gp. III). DOX-treated mice showed significant elevation in cardiac injury biomarkers (lactate dehydrogenase, creatine kinase isoenzyme-MB, and cardiac troponin I), cardiac oxidative stress (OS) markers (malondialdehyde and myeloperoxidase), and cardiac levels of autophagy-related protein 5. Moreover, DOX significantly reduced the levels of total antioxidant capacity and activities of catalase and glutathione S-transferase. In contrast, TRE treatment of DOX-administered mice significantly improved almost all of the above-mentioned assessed parameters. Furthermore, histopathological changes of cardiac tissues observed in mice treated with TRE in combination with DOX were significantly improved as compared to DOX-treated animals. Taken together, the present study provides evidence that TRE has cardioprotective effects against DIC, which is likely mediated via suppression of OS and autophagy.

Keywords: autophagy; cardiotoxicity; doxorubicin; oxidative stress; trehalose.

MeSH terms

  • Animals
  • Autophagy / drug effects*
  • Biomarkers / metabolism
  • Cardiotonic Agents / pharmacology*
  • Cardiotoxicity / drug therapy*
  • Cardiotoxicity / metabolism
  • Doxorubicin / adverse effects*
  • Doxorubicin / pharmacology
  • Female
  • Mice
  • Myocardium / metabolism
  • Oxidative Stress / drug effects*
  • Trehalose / pharmacology*

Substances

  • Biomarkers
  • Cardiotonic Agents
  • Doxorubicin
  • Trehalose